Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRL345 in Healthy Volunteers
NCT05408091Phase 1Completed
- Sponsor
- Trellis Bioscience
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRL345 in cytomegalovirus infection (CMV) (2 arms), sponsored by Trellis Bioscience. Primary endpoints: Incidence of Abnormal Physical Exam Findings at 11 weeks, Severity of Abnormal Physical Exam Findings at 11 weeks and 10 more. Started Sep 2023; status: completed.
02
Drugs
TRL345
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05408091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408091.